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Alginate Composition Effects
on a Neural Stem Cell–Seeded Scaffold
Erin K. Purcell, Ph.D., Aparna Singh, B.Tech., and Daryl R. Kipke, Ph.D.
The purpose of this study was to evaluate the effects of alginate composition on the neurotrophic factor release,
viability, and proliferation of encapsulated neural stem cells (NSCs), as well as on the mechanical stability of the
scaffold itself. Four compositions were tested: a high guluronic acid (68%) and a high mannuronic acid (54%)
content alginate, with or without a poly-L-lysine (PLL) coating layer. Enzyme-linked immunosorbent assay was
used to quantify the release of brain-derived neurotrophic factor, glial-derived neurotrophic factor, and nerve
growth factor from the encapsulated cells. All three factors were detected from encapsulated cells only when a
high L-guluronic acid alginate without PLL was used. Additionally, capsules with this composition remained
intact more frequently when exposed to solutions of low osmolarity, potentially indicating superior mechanical
stability. Alginate beads with a PLL-coated, high D-mannuronic acid composition were the most prone to
breakage in the osmotic pressure test, and were too fragile for histology and proliferation assays after 1 week
in vitro. NSCs survived and proliferated in the three remaining alginate compositions similarly over the 21-day
study course irrespective of scaffold condition. NSC-seeded alginate beads with a high L-guluronic acid,
non-PLL-coated composition may be useful in the repair of injured nervous tissue, where the mechanism is the
secretion of neuroprotective factors. We verify the neuroprotective effects of medium conditioned by NSC-
seeded alginate beads on the serum withdrawal–mediated death of PC-12 cells here.
Introduction
Alginate is a biocompatible hydrogel that has beenused to encapsulate many types of cells with the pur-
pose of immunoisolation from the host.1–4 Encapsulation
protects graft cells from potential damage caused by an im-
mune response while allowing the secretion of therapeutic
agents from the cells into the surrounding host tissue. Small
molecules such as glucose, oxygen, and waste products freely
pass through the gel matrix. Recent studies have investigated
the use of alginate as a neural stem cell (NSC) scaffold.5–7
However, the effect of alginate composition on NSC function
has not been investigated.
Administration of stem cells to sites of central nervous
system injury may be used as a means of replacing damaged
or diseased tissue, where the focus is on directing the dif-
ferentiation of implanted cells into neurons and subsequent
reinnervation of host tissue. This strategy has been used to
intervene in numerous sources of central nervous system
injury, including Parkinson’s disease, stroke, ALS, spinal cord
injury, traumatic brain injury, and Huntington’s disease.8–10
However, in many studies the degree of functional recov-
ery after NSC transplantation is not explained by the quan-
tity of differentiated graft cells alone, lending credence to a
bystander or supporting role of NSCs.9,11,12 Several studies
suggest that NSCs have an innate ability to promote neuro-
protection and axonal regeneration of host tissue.11,13–16 Po-
tential mechanisms include constitutive secretion of multiple
neurotrophic factors,11,14–16 as well as degrading molecules
that are inhibitory to axonal growth.13 NSCs derived from
various sources have been found to elute nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), glial-
derived neurotrophic factor (GDNF), and matrix metallo-
protease-2, which degrades chondroitin sulfate proteoglycan
(a molecule inhibitory to axonal growth).6,13–15 Thus, NSCs
and progenitor cells may be exploited as a sort of minia-
ture drug factory, releasing factors that result in the desired
healing response in injured nervous tissue. Encapsulation of
these cells in alginate may further enhance their therapeutic
utility by localizing the cells to the site of injury and isolating
them from a host immune response.
Alginate is a biocompatible polysaccharide polymer com-
posed of D-mannuronic (M) and L-guluronic acid (G) residues
in varying proportions. Cross-linking and gel formation takes
place when divalent cations, such as calcium, ionically bind
carboxylic acid groups of blocks of guluronic residues be-
tween chains. Alginate has been used widely to encapsulate
cells after ground-breaking work published by Lim and Sun
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in 1980, which demonstrated reversal of diabetes in rats im-
planted with alginate-encapsulated pancreatic islets for a pe-
riod of 2–3 weeks.3 Several studies have sought to understand
the relationship between alginate composition and the func-
tion of the graft.4,17–24 Two common themes emerge in the
literature regarding alginate composition and graft perfor-
mance: the effect of the M=G content of the alginate and the
importance of a polycation coating layer. These two variables
have been related to gel mechanical stability, viability of en-
capsulated cells, in vivo biocompatibility, and diffusion
through the alginate gel. In terms of mechanical stability, al-
ginates with a high G content are more mechanically stable
than those with a high M content.25 However, high G alginate
has been shown to initially inhibit the metabolic and secretory
activity of cells due to growth inhibition, theoretically because
a higher strength gel is more difficult for proliferating cells to
displace.17,21 Beads composed of high G alginate are also
known to be more porous than high M alginate, thus en-
hancing diffusion of molecules into and out of the matrix.26
Poly-L-lysine (PLL) coating is commonly employed as a
means of strengthening the alginate bead and providing a
barrier to immune system components such as IgG.27,28
However, the PLL coating layer may itself cause an unfa-
vorable foreign body response and slight toxicity to encap-
sulated cells, and its use remains controversial.19,20,22,23,29–31
In light of the extensive research indicating a relation-
ship between alginate composition and encapsulated cell
function, as well as the limited amount of data on NSC
encapsulation in alginate, the effects of M=G content and
PLL coating on entrapped cortical NSCs were investigated.
Among the conditions tested, we show that neurotrophic
factor release and mechanical stability in response to an os-
motic challenge were the most favorable with a high G
scaffold without a PLL coating layer. NSCs survived and
proliferated in alginate regardless of the compositions tested.
Neurotrophic factor release and bioactivity assay data sub-
stantiated the use of NSCs encapsulated in alginate to heal
injured nervous tissue via a bystander mechanism. These
scaffolded cells have therapeutic potential in treating ner-
vous system injuries in future studies, and current work
in our lab is investigating their ability to repair a cortical
lesion in the adult rat brain.32
Materials and Methods
Materials
Cortical NSCs, nestin antibody, neuronal class III b-
tubulin (TUJ-1) antibody, and all NSC cell culture reagents
were purchased from StemCell Technologies (Vancouver,
BC). 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and enzyme-
linked immunosorbent assay (ELISA) kits were obtained from
Promega Corporation (Madison, WI). Alginate was from No-
vaMatrix (Drammen, Norway). Live=Dead Assay and PC-12
medium reagents were from Invitrogen Corporation (Carls-
bad, CA). BD Biocoat collagen–coated plates were from BD
Biosciences (San Jose, CA). Centricon filters and NG-2 anti-
body were from Millipore Corporation (Billerica, MA). Sec-
ondary antibodies were from Molecular Probes (Eugene, OR).
PC-12 cells were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). All other reagents were
from Sigma-Aldrich (St. Louis, MO).
Cortical NSC culture and encapsulation in alginate
E14 murine cortical NSCs were cultured and expanded
with 20 ng=mL epidermal growth factor according to the
supplier’s protocol with a penicillin–streptomycin antibiotic
supplement. The culture and stem cell characteristics of these
cells have been described.33,34 Cell encapsulation (on Day 0)
was achieved by mixing a cell slurry with alginate 50:50 and
dropping into a 0.1 M calcium chloride solution for 10 min.
The encapsulation yielded beads with a final concentration
of 500,000 cells=mL in 1% w=v alginate (approximately 650
cells per bead). The weight percentage was chosen based on
a recommendation reported in the literature.21 Cells were
approximately 90% viable as assessed by trypan blue stain-
ing before encapsulation. Bead size was approximately 1 mm
in diameter (1.38 0.19 mm, mean SD, n¼ 158) immedi-
ately after production, and size was controlled by parallel air
flow through a glass atomizer. Four different conditions
were employed to optimize the encapsulation procedure: a
high G alginate (68% G content, molecular weight¼ 219,000
g=mol) or a high M alginate (54% M content, molecular
weight¼ 222,000 g=mol), with or without a PLL coating layer.
The conditions chosen have been shown to have differing
mechanical strengths based on M=G content, and molecu-
lar weights were closely matched to eliminate this factor as
an experimental variable.25,35 These conditions are abbrevi-
ated as G, M, G-PLL, and M-PLL. All alginates were highly
purified and sterile.
PLL coating was achieved as previously described.36
Briefly, beads were rinsed in physiological saline before a
10 min incubation in 0.1% PLL-HCl (15,000–30,000 MW) in
saline. After additional saline rinsing, beads were incubated
for 10 min in 0.1% alginate in saline. Beads received a final
rinse before being returned to medium. Beads were cultured
in static transwell dishes containing 500,000 cells (encapsu-
lated or unencapsulated) that were allowed to proliferate in
the presence of epidermal growth factor over time.
ELISA
At 1, 4, 7, 14, and 21 day time points, medium samples
were collected for quantification of growth factor release
with ELISA (n¼ 5 per condition). Untreated medium and
supernatant from nonencapsulated cells were used as con-
trols. Supernatant was concentrated with YM-3 Centricon
filters at 48C. Promega Emax ELISA kits for NGF, BDNF, and
GDNF were used according to the manufacturer’s protocol.
Average values below the lowest dilution above zero of the
standard curve for each kit were considered to be non-
detectable.
Alginate mechanical stability
The mechanical stability of the alginate beads was as-
sessed using a semi-quantitative osmotic pressure test.37
Testing was conducted at 1, 7, 14, and 21 day time points.
Alginate beads were exposed to solutions of low osmolarity
(0, 2.8, and 11.1 mOsm saline with medium used as a control)
for a period of 3 h, as previously described.37 Thirty beads
per condition were assessed visually for breakage at each
time point. The number of intact capsules was compared
between conditions by an observer blinded to the experi-
mental condition.
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NSC proliferation and viability in alginate
Beads were collected for quantification of proliferation
with an MTS assay and viability with propidium iodide
staining at the same time points as ELISA. In the MTS assay,
a tetrazolium compound is bioreduced by metabolically ac-
tive cells into a formazan product that is quantified by a plate
reader. Twenty beads per well (n¼ 4 wells per condition per
day) were assayed for each condition in accordance with
previously published methods and sample sizes in similar
studies.38
To assess the viability of the cells in the alginate, beads
were exposed to propidium iodide for 1.5 h and counter-
stained with Hoechst for the final 10 min (n¼ 4 per condi-
tion). Results were assessed by obtaining the percentage of
propidium iodide positive nuclei by counting under a Zeiss
Axioplan microscope. Slides were evaluated by an observer
blinded to the experimental condition.
Immunocytochemistry of cells in alginate
Beads were collected at the same time points as ELISA
for histology (n¼ 4 per condition). For all staining applica-
tions, beads were briefly fixed in phosphate buffered saline–
buffered 4% paraformaldehyde for 10 min followed by
dehydration in graded washes of ethanol up to 70%. The
samples were embedded in paraffin and sectioned on a mi-
crotome at a 5mm thickness. Sections were de-paraffinized,
rehydrated, blocked with 10% normal goat serum, and
stained with markers of differentiation. Specifically, immu-
nocytochemistry for TUJ-I (neuronal precursors), GFAP (as-
trocytes), NG-2 (oligodendrocyte precursors), and nestin
(undifferentiated NSCs) were performed based on a previ-
ously described method at 1:500, 1:80, 1:500, and 1:80 con-
centrations, respectively.39 Tris buffered saline was used in
place of phosphate buffered saline to improve bead stability
during staining by avoiding phosphate binding of calcium
cross-links. Nuclei were counterstained with Hoechst. As a
negative control, Tris buffered saline was used in place of
primary antibody. Analysis of results was a qualitative as-
sessment of histology.
Bioactivity of conditioned medium
from NSC-seeded beads
To verify the potential ability of cortical NSCs to exert
neuroprotective effects via a bystander mechanism when
encapsulated in alginate, a serum-withdrawal model of
apoptosis in PC-12 cells was used.6 PC-12 cells were cul-
tured in RPMI-1640 medium supplemented with 10% heat-
inactivated horse serum and 5% fetal bovine serum on type
IV collagen–coated 96-well plates, based on methods previ-
ously described.40 To obtain conditioned medium, NSCs
were encapsulated in 1% high G alginate, and medium was
collected 48 h later. The high G alginate scaffold was cho-
sen for this experiment based on its improved mechani-
cal stability and support of neurotrophic factor release as
demonstrated in this study. Nonseeded alginate beads con-
ditioned the control medium. Fifty percent of serum-
containing medium was removed and replaced with either
NSC-conditioned or control medium (from empty capsules).
Control cells were given a medium change only. Twenty-
four and 48 hours later, PC-12s were evaluated for viability
with a Live=Dead kit. The center of each well was imaged
with the 20 objective of a Leica inverted microscope, and
live and dead cells were counted by an observer blinded to
the experimental condition with ImageJ software (U. S. Na-
tional Institutes of Health, Bethesda, MD). The experiment
was repeated, and a univariate ANOVA model that factored
in time and trial was used to evaluate the combined data.
Cell viability was evaluated as a percent of control.
Statistical analysis
Differences between controls and experimental conditions
for ELISA, MTS values, NSC, and PC-12 viability were
analyzed with standard analysis of variance (ANOVA) tech-
niques and a Tukey posthoc test where significance was noted.
Osmotic pressure test data were analyzed with logistic re-
gression due to the binary response variable (1¼ intact bead,
0¼ broken bead). Histology was evaluated on a qualitative
basis. Statistical significance was defined at the 0.05 level.
Results
ELISA
The amount of NGF secreted from the unencapsulated cells
(roughly between 10 and 90 pg=million cells=day depending
on time point; Table 1) was similar to that previously reported
from the C17.2 NSC line derived from cerebellum (approxi-
mately 10 pg=million cells=day), and NGF secreted from cells
in G capsules also fell within this range.15 GDNF secretion
from unencapsulated and G encapsulated cells on day 14 was
somewhat higher than the value reported for the C17.2 clone
(70 pg=million cells=day) (Table 1).15 No secretion of NGF or
GDNF was detected at any time point from cells encapsulated
in other scaffold conditions. NGF was detected on fewer days
from G encapsulated cells compared with unencapsulated
cells (Table 1). BDNF was detected from all conditions, both
encapsulated and unencapsulated, at the 4 day time point,
and values were generally higher than that reported for C17.2
cells (10 pg=million cells=day) (Table 1).15 The 4 day time
point is also when cell viability tended to be at its lowest levels
for scaffold conditions; it is unknown if the two phenomena
are related (Fig. 2a). NGF levels for unencapsulated cells were
higher at 7 and 21 days than at initial time points; no other
significant differences were found.
Alginate mechanical stability
G beads were significantly more stable than all other con-
ditions when exposed to solutions of low osmolarity (Fig. 1a,
p< 0.001). The odds of beads remaining intact was increased
by at least 18-fold in comparison to other conditions when a
high G composition was used. Representative images of beads
exposed to 0 mOsm solutions after 7 days in vitro further
highlight the improved stability of high G beads compared
with other alginate compositions during this test (Fig. 1b–e).
High M beads were more stable than PLL-coated beads (Fig.
1a, p< 0.001). The data show that PLL coating resulted in
increased incidence of bead breakage, with no significant
difference between G-PLL and M-PLL beads. The presence of
a PLL coating layer was visually confirmed in a separate in-
vestigation using the same coating protocol with FITC-labeled
PLL and fluorescence microscopy (data not shown). There
was a significant reduction of alginate stability after 24 h; the
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odds of beads being intact decreased ninefold after this time
point (Fig. 1a, p< 0.001). No further significant changes in
stability over time were observed. Similar results were found
when beads were exposed to solutions of 2.8 and 11.1 mOsm
saline (data not shown).
Proliferation and viability in alginate
NSCs survive and proliferate in all alginate matrices re-
gardless of composition (Fig. 2a–d). M-PLL capsules were
too mechanically unstable to assay after the first week. After
an initial drop in viability at 4 days to the 20–40% range,
cell viability rebounds to over 70% thereafter regardless of
encapsulation condition (Fig. 2a, p< 0.05). Cell death levels
were high immediately after encapsulation, mainly due to
necrosis with many cells appearing to be lysed by the pro-
cedure. Day 1 viability data likely underestimate the extent
of cell death after encapsulation; cellular debris was evident
at this time point, and many cells may not have been ana-
lyzed due to degradation. Representative pictures of healthy
and propidium iodide–positive cells from the same sample
of high G-encapsulated neurospheres are shown in Figure
2b–c. Cells at the interior of larger encapsulated neuro-
spheres are particularly vulnerable to necrosis, presumably
due to reduced nutrient and oxygen diffusion (Fig. 2c). At
later time points, chromatin clumping possibly indicating
apoptosis was seen in a few cells, and much lower levels
of necrosis occurred. There were no significant differences
in viability between alginate conditions. An MTS assay re-
vealed cell proliferation in all alginate matrices irrespective
of composition, and cell number was above the detection
limit of the assay (estimated to be *2000 NSCs per well)
beginning at 4 days postencapsulation. Cell number was
significantly increased over the 4 day value by the 21 day
time point (Fig. 2d, p< 0.05). Previous experiments visually
validated the MTS assay of alginate beads with toluidene
blue staining of paraffin sections (data not shown). The data
indicate that NSCs survive and proliferate within alginate
matrices after an initial drop in viability regardless of com-
position, likely due to the physiological challenge the en-
capsulation procedure presents to the cells.
Immunocytochemistry of cells in alginate
Results of immunocytochemistry were limited due to bead
instability during staining, and dehydration and processing
seemed to affect tissue appearance. However, preliminary
results revealed that encapsulated NSCs express nestin on
the periphery and GFAP in the center of larger proliferating
cell masses after entrapment in alginate (Fig. 3a–b). Smaller
neurospheres were often nestin positive and largely GFAP
negative (data not shown). This profile of expression is typical
for that observed with similar neurosphere-derived cells in
culture.41 No expression of TUJ-1 was observed. Interestingly,
some evidence of limited NG-2 expression was observed in
one bead, indicating oligodendrocyte precursors (Fig. 3c).
Bioactivity of conditioned medium
from NSC-seeded beads
Results of a viability assay revealed a significant protec-
tive effect of conditioned medium collected from NSCs en-
capsulated in G beads against serum withdrawal–mediated
PC-12 cell death over 48 h (Fig. 4a, p< 0.05). These results are
novel for cortical NSCs, and corroborate a similar study done
with hippocampal NSCs.6 Representative images of live and
dead PC-12 cells are shown for NSC-conditioned and control
medium treatments in Figure 4b and c, respectively.
Table 1. Neurotrophic Factor Release Varies with Scaffold Condition and Time
Days
1 4 7 14 21
Cells NGF 30.98 5.64 19.18 8.17 74.19 26.01a 44.76 9.25 89.20 11.87b
GDNF ND ND ND 156.47 39.47 ND
BDNF ND 141.89 82.99 ND ND ND
G NGF 33.52 10.34 ND 26.67 12.23 ND ND
GDNF ND ND ND 296.19 175.72 ND
BDNF ND 173.98 36.52 ND ND ND
M NGF ND ND ND ND ND
GDNF ND ND ND ND ND
BDNF ND 50.96 9.07 ND ND ND
G=PLL NGF ND ND ND ND ND
GDNF ND ND ND ND ND
BDNF ND 161.74 52.07 ND ND ND
M=PLL NGF ND ND ND ND=NP ND=NP
GDNF ND ND ND ND=NP ND=NP
BDNF ND 102.30 59.86 ND ND=NP ND=NP
Values are given in pg=million cells=day. Unencapsulated cells secrete nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), and glial-derived neurotrophic factor (GDNF) at various time points throughout the study, whereas all three factors were detected
from encapsulated cells only when a high G alginate scaffold was used. BDNF was detected from all conditions at the 4 day time point, and
GDNF was detected at the 14 day time point from G-encapsulated and unencapsulated cells. NGF secretion from unencapsulated cells at 21
days was significantly greater than 1 day and 4 day values (b), and secretion at 7 days was greater than 4 day values (a) ( p< 0.05, ANOVA).
Medium samples were assayed throughout the study regardless of the mechanical integrity of the alginate beads. Nondetectable values are
denoted ‘‘ND.’’ Medium samples assayed from time points in which beads degraded and were no longer present are labeled ‘‘NP’’ (not
present). Mean SEM is shown. G, L-guluronic acid; M, D-mannuronic acid; PLL, poly-L-lysine.
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Discussion
Alginate composition has been shown to affect encapsu-
lated cell proliferation and secretion of therapeutic proteins,
as well as the mechanical stability of the scaffold.17,21,25 We
sought to characterize the effects composition may have on
NSCs, as alginate is largely unstudied as a carrier for these
cells. NSCs survive and proliferate in alginate irrespective of
the scaffold compositions tested in this study. Among the
conditions tested, a high G content alginate without a PLL
coating layer was the optimal composition based on its me-
chanical stability during the osmotic pressure test and sup-
port of neurotrophic factor release.
Our data reveal that cortical NSCs, even when encapsu-
lated in alginate, secrete NGF, BDNF and GDNF into the
surrounding medium. Importantly, these neurotrophic fac-
tors are known to support neuronal survival and plasticity in
various models of axonopathy and neuropathy.42–46 Quan-
titative analysis of constitutive neurotrophic factor release
from NSCs is relatively rarely reported in the literature, de-
spite the popular theory that release of these proteins and
their effects on compromised host tissue is a potential mech-
anism behind the cells’ restorative capacity.8,9,11,14,16 Time
courses of release are generally lacking, as are release profiles
from scaffolded cells. Lu et al. reported detection of NGF,
BDNF, and GDNF in medium collected from C17.2 NSCs
after a 24 h time point, with levels in the 10–70 pg=million
cells=day range.15 GDNF and NGF, but not BDNF, secretion
was detected from these cells in a separate report.14 GDNF
release from alginate encapsulated and unencapsulated hip-
pocampal NSCs tended to be approximately 500–1000 pg=
million cells after 72 h, as reported by Li et al.6 Therefore, the
reported values for neurotrophic factor release from encap-
sulated and unencapsulated cells differ from 10 to 1000 pg=
million cells, and our results are consistent with this range.
This study revealed that the detection of released neuro-
trophic factors is influenced by alginate composition and
time. BDNF and GDNF are detected at single time points (4
FIG. 1. Neural stem cell (NSC)-seeded
alginate microcapsules with a G compo-
sition have superior stability in compar-
ison to all other conditions. G beads
remain intact more frequently than M
capsules after exposure to 0 mOsm 7
days after seeding (a) ( p< 0.001, logistic
regression). Poly-L-lysine (PLL)-coated
capsules break more frequently than
uncoated capsules ( p< 0.001, logistic
regression). Representative images of G
(b), G-PLL (c), M (d), and M-PLL (e)
capsules in solution illustrate the stabil-
ity of G capsules (intact beads are labeled
‘‘I’’) and breakage (broken beads are
denoted ‘‘B’’) of M and G-PLL beads.
M-PLL beads are completely dissolved.
Insets in (b–d) highlight representative
beads (arrows) to improve observation.
Error bars are not shown due to the na-
ture of the data analysis. Scale¼ 1 mm.
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and 14 days, respectively), while NGF release is observed
throughout the study by unencapsulated and encapsulated
cells. NGF is detected on fewer days (occurring only in the
first week postencapsulation) from encapsulated cells in
comparison to unencapsulated cells, possibly due to the
initial reduction in viability of the cells by encapsulation,
degradation of the NGF protein, or interactions of NGF with
the alginate matrix. Alternatively, this result may be related
to the apparently lower proliferation rate of NSCs in alginate
matrix; the proliferation data shown in Figure 2d do not
reflect the 2.5 day doubling rate unencapsulated cells typi-
cally experience in culture. GDNF and NGF are only
detected from encapsulated cells when a high G, non-
PLL-coated capsule is used. Meanwhile, BDNF is released
from cells in all conditions tested. Why the high G alginate
capsules seem more permissive to neurotrophic factor release
is unclear, given that previous literature for insulin-secreting
cells has suggested reduced proliferation and less secretion at
early time points for cells encapsulated in high G alginate.21
No significant effect of alginate composition on NSC prolif-
eration was demonstrated here, which may be due to the
relatively low alginate weight percentage (1%) used, as well
FIG. 2. NSCs survive (a–c) and prolif-
erate (d) in alginate regardless of the
compositions tested. Viability of the
cells is initially reduced after encapsula-
tion, but significantly improves for all
conditions after 1 week (a). Cells are la-
beled with Hoechst (blue), and propidium
iodide (red) stains nuclei of cells with
compromised membranes indicative of
cell death (b–c). Images of G-
encapsulated cells at 21 days illustrate the
vulnerability of cells in the center of larger
proliferating neurospheres to necrosis,
presumably due to reduced nutrient and
oxygen diffusion (b–c). NSCs proliferate
irrespective of alginate composition, and
cell number was significantly increased 21
days postencapsulation over initial
4-day quantities (d). Values were initially
nondetectable by the MTS assay 1 day
after encapsulation (d). M-PLL capsules
were too mechanically unstable to assay
after the first week. {Significantly in-
creased versus 1 and 4 day values at the
0.05 level (ANOVA). Mean standard
error of the mean (SEM) is shown.
Scale¼ 100mm. Color images available
online at www.liebertonline.com=ten.
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as differences in the cell types studied. Additionally, the in-
creased gel porosity of high G alginate (which could be
further enhanced by swelling) and the potential for stabili-
zation of trophic factors by interaction with the alginate
matrix are possible explanations.26,47 Since neurotrophic
factors are larger than insulin (approximately 20–30 kDa vs.
5 kDa), the increased porosity of high G alginate may be
necessary to allow for adequate release. The release timing of
individual neurotrophic factors may be explained by cellu-
lar events and their relationship to evolving environmental
cues, and the quantities and timing of neurotrophic factor
release is likely to vary with culture conditions. BDNF re-
lease coincided with low cell viability, while GDNF detection
occurred at a time of increased viability and cell number. It is
important to note that the initial drop in viability after en-
capsulation could affect the types and quantities of trophic
factors released from the cells. Further, the traits of the in-
dividual neurotrophic factors may have been a factor in their
detection. Specifically, the relatively larger size of GDNF
may have resulted in its detection at fewer time points in
comparison to NGF. While electrostatic interactions with the
alginate matrix require consideration, the neurotrophic fac-
tors studied here all have similar basic isoelectric points
(ranging from 9 to 10), indicating that they each carry a net
positive charge at physiological pH. Cellular events, protein
characteristics, and their relationships to interactions with
the alginate matrices may all play a role in the detection of
the neurotrophic factors. However, elucidating the mecha-
nisms behind the release profile of neurotrophic factors by
the NSCs is beyond the scope of the current work.
The mechanical stability of alginate in vivo over time remains
an important challenge.29,48 In a cell encapsulation application,
alginate localizes graft cells to the transplant site and isolates
them from the immune response, and loss of mechanical
strength may compromise these functions. Alginates with a
high G content are known to be more mechanically stable than
those with higher M contents, due to stabilization by addi-
tional cross-links.25 That result was verified here, where the
stability of alginate capsules of varying compositions was semi-
quantitatively compared by an osmotic pressure test. High G
capsules remained intact far more frequently when exposed
to solutions of low osmolarities compared with M beads and
PLL-coated conditions, and no evidence of decreased prolifer-
ation and therapeutic factor secretion was observed. A tradeoff
between cellular function and scaffold mechanical strength has
been reported previously with insulin-secreting cells.21 How-
ever, this tradeoff was more pronounced for higher weight
percentage (2%) alginates than the weight percentage (1%)
used here. Additionally, this phenomenon was reported for a
markedly different cell type than the one studied here, with
presumably substantial impacts on proliferation and secretion
characteristics.
It was somewhat surprising that the PLL-coated capsules
were more prone to breakage than uncoated beads during the
osmotic pressure test, given that PLL has been credited with
improving mechanical stability.20,49 This evidence requires
careful interpretation, with consideration for the consequences
of saline washing, the potential effects of polycation coating on
swelling behavior, the impact of alginate concentration, and the
definition of mechanical stability. The results may be affected
by the multiple saline washes used in the coating protocol.
Monovalent sodium ions may compete with divalent calcium
ions for binding sites between G residues, and ultimately break
the cross-links and weaken the gel.50 We have previously re-
ported a study in which uncoated and PLL-coated alginate
disks were washed identically in saline, implanted subcuta-
neously in rats, and monitored over 3 months for mechanical
stability, weight changes related to swelling behavior, and
biocompatibility.48 PLL-coating resulted in a slight but signif-
icant increase in complex modulus 7 days after implantation in
comparison to noncoated gels; no other significant differences
in stability between the two conditions were noted. Therefore,
PLL coating may confer a slight advantage, or at least have a
nondetrimental role, on gel stability when results are not af-
fected by saline washing. However, saline washing is a pro-
totypic part of PLL coating protocols; thus, if coating is
pursued, the current results indicate that the potentially de-
stabilizing effects of saline washing should be considered.
In the same study, both PLL and noncoated gels initially
dropped in weight after implantation, followed by similar
trends in increasing weight (interpreted as swelling) for
a period of 2 weeks. The weight gains were greater for
FIG. 3. Encapsulated NSCs express nestin (green) on the periphery and GFAP (red) in the center of cell masses after
entrapment in alginate (a–b). Interestingly, some evidence of limited NG-2 expression (green) was observed in one bead,
indicating oligodendrocyte progenitors (c). All nuclei were counterstained with Hoechst (blue). Images are from (a) G, 14 day
(b) M-PLL, 14 day, and (c) G-PLL, 4 day, scaffolds and time points. Scale¼ 50mm. Color images available online at
www.liebertonline.com=ten.
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noncoated than PLL-coated samples, potentially indicating
greater swelling. Previous research has indicated that os-
motic swelling of the bead core against a less elastic poly-
cation membrane may eventually cause capsules to burst.51
Therefore, although the G capsules may not burst, they may
swell during exposure to an osmotic challenge, likely
changing diffusion properties (which may, in turn, be related
to their permissiveness to neurotrophic factor release).27 The
capsules in this study may be particularly vulnerable to
swelling and saline effects due to the relatively low weight
percentage used (1%); increased alginate concentration im-
proves resistance to swelling.50 Finally, the way in which
mechanical stability is measured (i.e., rheology in the in vivo
study and osmotic pressure in the in vitro study) is likely to
affect results. De Castro et al. reported PLL coating to confer
superior resistance to compression, but the lowest resistance
to osmotic pressure, in a mechanical stability test of three
different polycation coatings.52
The authors in the current study hypothesize that alginate
beads were initially weakened by saline washes before PLL
coating, and swelled in response to solutions of low osmo-
larity against the PLL coating, causing them to burst. Thus,
the mechanical stability of uncoated beads was improved
compared with coated beads in the current experiment, but
consideration for the effects of saline washing, swelling be-
havior, and changes in diffusion characteristics is required.
Importantly, PLL coating has been credited with isolating
alginate from IgG and complement diffusion into the gel.
The coating protocol used in the experiments reported here
was recommended to achieve this property.28 However,
FIG. 4. NSC-conditioned medium from G-encapsulated cells protects PC-12 cells from serum withdrawal–mediated cell
death (a) ( p< 0.05, ANOVA). Representative images of live (green) and dead (red) PC-12 cells after a 50% serum withdrawal
and treatment with medium conditioned by NSC-seeded (b, 75.6% viable) or unseeded (c, 49.5% viable) alginate micro-
spheres. Results are reported as a percentage of control PC-12 cell viability. Mean SEM is shown. Scale¼ 100 mm. Color
images available online at www.liebertonline.com=ten.
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polycation coatings are still controversial after over 25 years
of research due to the fact that they may directly elicit a
tissue response.19,22,23,29–31 In addition to the questionable
effect on in vivo biocompatibility, our data demonstrate bead
breakage during an osmotic challenge and reduced neuro-
trophic factor detection associated with PLL coating.
Our results indicate that a high G alginate without PLL
coating was the most favorable composition for NSC en-
capsulation among the conditions tested based on superior
mechanical stability during the osmotic pressure test and
support of neurotrophic factor release. However, several
opportunities for further development remain. Alternative
polycations or a different polycation coating procedure may
allow for tailoring diffusivity properties without a loss in
mechanical stability or neurotrophic factor detection.29 Al-
ginate weight percentage variation, bead size reduction, and
incorporation of interpenetrating networks are additional
examples of methods that may improve results.21,53–55 We
are currently evaluating the ability of a high G, non-PLL-
coated alginate scaffold seeded with NSCs to repair a cortical
lesion in vivo, and early results are promising.32
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